U.K. Industry Asks For More Time To Prepare For Limits On OTC PSE Sales
This article was originally published in The Tan Sheet
Executive Summary
U.K. drug firms say the country's regulatory agency is not allowing enough time to comply with an order banning nonprescription access to product packages with more than 720 mg of pseudoephedrine beginning April 1
You may also be interested in...
U.K. to keep PSE meds BTC
Restrictions on sales of drugs containing ephedrine and pseudoephedrine in the U.K. have proven effective in decreasing illicit methylamphetamine production, so the Medicines and Healthcare products Regulatory Agency will not shift the products to prescription only status. In August 2007, an agency advisory panel recommended ephedrine and PSE products be sold in packages no larger than 720 mg and its Commission on Human Medicines recommended limiting sales of the drugs to pharmacy only and to one package per person (1"The Tan Sheet" Jan. 14, 2008). MHRA said July 29 in wake of the changes, meth abuse has been contained and pharmacies have seen a 25 percent drop in PSE purchases. An executive said the agency will continue to monitor sales of the meth precursors
Prescription Status For Pseudoephedrine In U.K. Put On Hold For Two Years
The British health authority will move pseudoephedrine- and ephedrine-containing OTCs to prescription-only status in two years unless the risk of the products' use in the illicit manufacturing of methamphetamine decreases by that time
Jurors' Answers In FTC's Prevagen Complaint Might Burst A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.